


# Proposition for a general antiplatelet prophylaxis strategy

#### Ruth Heying Pediatric Cardiology, KU Leuven

### IE: Societal challenges

#### Risk of IE Factors increasing risk of IE



invasive medical treatment <sup>↑ S. aureus IE</sup> antibiotic resistance age of population and patients

limited effect of prophylaxis

van Dijk et al 2015, Heart

Endocardetis Subacute Bacterial 3278 Hermated Stre in blood Mahle Sustar Mables and LV III

Front page of George Baehr and Emanuel Libman's bacteriological report on Mahler's blood culture.

# Diagnostik gestützt wird. Der Kardiologe Libman hat sich über ein Jahrzehnt lang mit der neuen Technik der Blutkultur befasst und etwa 3 000 Kulturen untersucht (17). Doch es soll noch eine ganze Zeit dauern, bis eine wirksame Therapie verfügbar ist.

Mahler wird mit einer experimentellen Serumtherapie und symptomatisch mit Acetylsalicylsäure, die gerade erst seit 1897 in reiner Form synthetisiert werden kann, behandelt. Eine Heilung ist damit natürlich nicht möglich. 1909 entwickelten Paul Ehrlich und Sahachiro Hata das Salvarsan und 1932 von Mietch und Klarer ein Sulfonamid, das unter dem Namen Prontosil bekanntwurde. Dessen antibakterielle


Gustav Mahler, 1911

Mahler received an experimental serum therapy and was symptomatically treated with aspirin, which could be synthesized since 1897.

# Role of antiplatelet agents in IE prevention?

## Mechanisms anti-aggregant therapy


- ASA: irreversible inhibition of cyclooxygenases (COX)
- prostaglandine
- I thromboxane A2
- Clopidogrel,
  Ticagrelor:
- inhibition of platelet adenosindiphosphate (ADP) receptor




## IE Prophylaxe?

#### Prophylaxis of Experimental Endocarditis With Antiplatelet and Antithrombin Agents: A Role for Long-term Prevention of IE in Humans?

Veloso TR et al, J Infect Dis 2015, 211(1); 72-79



#### Anti-platelet agents prophylactic efficacy



\* P < 0.05 compared to control


Veloso TR et al, J Infect Dis 2015, 211(1); 72-79

#### Low-Dose Acetylsalicylic Acid Treatment and Impact on Short-Term Mortality in *Staphylococcus aureus* Bloodstream Infection: A Propensity Score-Matched Cohort Study

Michael Osthoff, MD<sup>1</sup>; Jan A. Sidler, MD<sup>1</sup>; Botond Lakatos, MD<sup>1</sup>; Reno Frei, MD<sup>2</sup>; Marc Dangel, MPH<sup>1</sup>; Maja Weisser, MD<sup>1</sup>; Manuel Battegay, MD<sup>1</sup>; Andreas F. Widmer, MD, MS<sup>1</sup>

- retrospective study of 839 S. aureus and 602 E. coli bloodstream infection episodes
- matching of low dose ASA users and non-users

Osthoff et al, Crit Care Med 2016, 44(4); 773-781



**Figure 2.** Survival curves in propensity score–matched low-dose acetylsalicylic acid (ASA) users and nonusers with *Staphylococcus aureus* bloodstream infection; Kaplan-Meier estimates. BSI = bloodstream infection.


# Role of fibrin and platelets



Fibrin deposition in the valvular sinus (Brown Hopps staining)


 predisposition for bacterial and platelet adhesion?


#### Platelet adhesion to RVOT tissues



#### Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria.


Lancellotti P<sup>1,2</sup>, Musumeci L<sup>1</sup>, Jacques N<sup>1</sup>, Servais L<sup>1</sup>, Goffin E<sup>1,3</sup>, Pirotte B<sup>3</sup>, Oury C<sup>1</sup>.






Bioluminescent signals of in vivo bactericidal activity

#### S. aureus and platelets



Fitzgerald et al. Nature Rev Microbiol 2005; 4:445-57

### Its just common sense



Courtsey from P. Moreillon

## In-vivo anti-platelet therapy

Hypothesis

Aspirin and platelet ADP receptor antagonists could diminish bacterial-platelet interaction with valvular tissue and thus be beneficial in IE prevention.




## Planned analysis

## IE databank UZ Leuven

- W. Oosterlinck, Cardiac Surgery
- M.C. Herregods, Cardiology
- W. Peetermans, Infectious Diseases
- > 740 adult patients, 2000 2019
- modified Duke criteria
- treatment conform to ESC guidelines

Cooperation with P. Moreillon and J. Entenza, Exp. Microbiology, Lausanne



## Planned analysis

#### Retrospective and prospective case control study

#### Patients

bioprosthetic aortic valve with native aortic valve

- $\rightarrow$  IE vs. non IE
- $\rightarrow$  ASA vs. no ASA

(odds-ratio and chi-square test)

250 patients in each group (power of 80 % of the analysis)

- risk of IE 0.7 % / patient year after bio-prosthetic valve
- 10 % of patients under ASA
- estimated decrease of IE risk under ASA 50 %



Feasibility of multi-center study


- ? participation of other centers
- ? patient cohort



? expansion to other anti-coagulant agents

ausanne

Limited Effect of Antibiotic Prophylaxis



van der Meer 1992. Lancet; 339:135-9 Wilson et al. Circulation 2007 Oct 9;116(15):e376-7.

courtsey from P. Moreillon, Lausanne